· Published by Health Canada · Official notice
This is duplicated text of a letter from Pfizer Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
June 3, 2010
Subject: Important Safety Information regarding CHAMPIX® (varenicline tartrate)
Pfizer Canada, in collaboration with Health Canada, is advising consumers of important changes to the CHAMPIX® Product Monograph and Consumer Information section.
These changes include:
CHAMPIX® (varenicline tartrate) is a prescription medicine that is used in combination with supportive counselling to help motivated adults quit smoking.
Patients using CHAMPIX® should stop the treatment and contact their healthcare provider immediately if they experience, or if their families or caregivers observe, signs or symptoms including:
Patients should also be aware that:
A letter has been posted to healthcare professionals on the Health Canada Web site.
Managing marketed health product-related adverse reactions depends on healthcare professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving CHAMPIX® should be reported to Pfizer Canada or Health Canada at the following addresses:
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, QC H9J 2M5
Telephone: 1-800-463-6001
Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701E
Ottawa, Ontario, K1A 0K9
Telephone: 613-957-0337 or Fax: 613-957-0335
CanadaVigilance@hc-sc.gc.ca
To report an Adverse Reaction, consumers and health professionals may call toll free:
Telephone: 1-866-234-2345
Fax: 1-866-678-6789
Postage paid labels, the Canada Vigilance Reporting Forms and the Adverse Reaction Reporting Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
To change your mailing address or fax number, contact the Market Authorization Holder (industry).
Sincerely,
original signed by
Bernard Prigent, MD, MBA
Vice-President and Medical Director
Pfizer Canada Inc.
® C.P. Pharmaceuticals International C.V.
Pfizer Canada Inc., licensee